CLSA Events

Therapeutic Focus | Drug and Biomarker Developments: The Evolution of Blockbusters?

The promise of personalized medicine has begun to be realized with several commercially successful products, notably Herceptin, Gleevec, and Rituxan that all rival conventional “blockbusters.” Higher rates of efficacy and more efficient (and therefore cost effective) trials have made products based on biomarkers increasingly intriguing and attractive to an industry chronically beset with R&D failures. Should we expect life science and pharma companies to embrace the biomarker strategy as their primary business model, or will biomarker-derived products remain a niche market? And should diagnostics be developed in tandem with pharmaceuticals or independently? A panel of experienced industry executives will focus on the real world experiences and will provide valuable insight into business and regulatory landscape surrounding biomarker technology.

Panel Moderator

Michael J. Shuster, PhD
Fenwick & West LLP

Panel Speakers

Rowan Chapman
Mohr Davidow Ventures

Mitch Raponi PhD
Sr. Director, Molecular Diagnostics
Clovis Oncology

Gary Yeung
Senior Director and Head of Project Management
Genentech, Inc.

Eric Whitters
Vice President, Research
Novartis Diagnostics

What: Therapeutic Focus:
Drug and Biomarker Developments:
The Evolution of Blockbusters?
When: Thursday, October 21, 2010
Registration Opens: 3:30pm
Panel Presentation: 4:00pm – 5:30pm
Networking Reception: 5:30pm – 6:30pm
Where: South San Francisco Conference Center,
255 South Airport Blvd.,
South San Francisco, CA
Attire: Business Attire Suggested